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Objective. The objective is the investigation of Joint Hypermobility (JH) and the Hypermobility Syndrome (HMS) in patients with
inﬂammatory bowel disease (IBD). Methods. We examined 83 patients with IBD and 67 healthy individuals for the presence of JH.
Patients were excluded if they were under 18 or over 50 years of age and if they had other conditions which aﬀect joint mobility.
The x2 and the Fisher exact test were used appropriately between study groups. Odds ratios (ORs) for the risk of JH and HMS in
IBD groups were calculated. Results. A total of 150 individuals (83 IBD patients and 67 healthy controls) participated in the study.
69 IBD patients, 41 with Crohn’s Disease (CD) and 28 with ulcerative colitis (UC), were ﬁnally eligible. JH was detected in 29 CD
patients (70.7%), in 10 UC patients (35.7%), and in 17 healthy control subjects (25.4%). Signiﬁcant diﬀerence was detected on
JH in CD patients as compared to UC patients (P = .0063) and controls (P<. 0001). The estimated OR for JH was 7.108 (95%
CI: 2.98–16.95) in CD and 1.634 (95% CI: 0.63–4.22) in UC patients. HMS was detected in 5 (12.2%) CD and in 1 (3.57%) UC
patients. The OR for HMS in CD was 3.75 (95% CI: 0.41–34.007), while 7 (17.1%) CD patients had overlapping symptoms for
both HMS and early spondylarthropathy. Conclusions. JH and the HMS are common in CD patients, thus articular manifestations
should be carefully interpreted. This implies an involvement of collagen varieties in the pathogenesis of IBD.
Copyright © 2009 P. Vounotrypidis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Joint hypermobility (JH) is a condition characterized by
joint laxity and an increased range of joint motion. In
general population is deemed as the upper range of a
normal distribution while it is also a feature of genetic
disorders such as Marfan’s, Ehlers-Danlos syndromes and
Osteogenesis Imperfecta. There are marked ethnic, age and
gender diﬀerences in articular mobility. Beighton’s scoring
method(Table 1)incorporates nine sites to evaluatearticular
mobility and it is widely accepted and easily applicable
in the clinical practice. In some individuals JH gives rise
to musculoskeletal problems the so called hypermobility
syndrome (HMS).
Followingtheﬁrstassociationbetweenjointhypermobil-
ity and musculoskeletal complaints ninety years ago and the
deﬁnite description of HMS, in recent years many reports
have found publicity on various extra-articular manifes-
tations of JH and its association to HMS. There are no
publishedstudiesofbenignJHinpatientswithinﬂammatory
boweldisease(IBD).Triggerof thestudywastheobservation
that patients with IBD appeared to have hypermobile joints.2 Gastroenterology Research and Practice
Table 1: Beighton’s joint hypermobility score.
The ability to Right Left
(1) Passively dorsiﬂex the ﬁfth
metacarpeophalangeal joint to ≥90◦ 11
(2) Oppose the thumb to the volar aspect
of the ipsilateral forearm
11
(3) Hyperextend the elbow to ≥10◦ 11
(4) Hyperextend the knee to ≥10◦ 11
(5) Place hands ﬂat on the ﬂoor without
bending the knees
1
Total possible score 9
One point can be gained for each side for manoeuvres 1–4 so that the
hypermobility score will have a maximum of 9 points if all are positive.
The aim of this study was to formally evaluate the incidence
of joint hypermobility and the hypermobility syndrome in
patients with Crohn’s disease (CD) and ulcerative colitis
(UC).
There are no published studies of benign joint hyper-
mobility in patients with inﬂammatory bowel disease (IBD).
Triggerofthestudywasanobservation,inasettingofacom-
bined gastroenterology and rheumatology outpatient clinic
that patients with IBD appeared to have hypermobile joints.
The aim of this study was to formally evaluate the incidence
of joint hypermobility and the hypermobility syndrome in
patients with Crohn’s disease (CD) and ulcerative colitis
(UC).
2. Patientsand Methods
In the study enrolled 83 patients with IBD who attended
consecutively, between January 2007 and September 2008,
the Inﬂammatory Bowel Diseases outpatient clinic at the
University Hospital of Alexandroupolis. For the prospective
cohort,patienthistorywasobtained,andaphysicalexamina-
tion was performed in all cases by the same rheumatologist
(PV).Werecordedthefamilialhistoryregardingthepresence
ofIBD,ankylosingspondylitis,psoriasisandfeaturesofJHin
the ﬁrst degree relatives of patients.
Initially the rheumatologist was not blinded for the diag-
nosis of IBD. This was the period in which the observation
of the increased incidence of joint hypermobility in patients
with CD was made. Twenty eight patients (33.7%) were
examined in non blinded fashion.
The joint laxity was evaluated using Beighton’s scoring
method. Meanwhile the 1998 Brighton’s criteria were used to
identify patients with HMS (Table 2)[ 1].
Radiological evidence of sacroiliitis and the pres-
ence of synovitis established the diagnosis of seronegative
enteropathic ankylosing spondylitis-spondyloarthritis (SpA)
according to the European Spondylarthropathy Study Group
(ESSG) criteria.
The diagnosis of Crohn’s disease and ulcerative colitis
hadbeenestablishedbythestandardclinical,endoscopicand
histologic criteria.
Table 2: Brighton’s diagnosticcriteriaforhypermobilitysyndrome.
Major Criteria
Beighton score 4/9 or greater (either currently or historically)
Arthralgia for longer than 3 months in 4 or more joints
Minor criteria
Beighton score of 1–3/9 (0–3 if aged 50+)
Arthralgia in 1–3 joints or back pain or spondylosis,
spondylolisthesis
Dislocation in more than 1 joint, or in 1 joint or more on more
than 1 occasion
Three or more soft tissue lesions (e.g., epicondylitis, tenosynovitis,
bursitis)
Marfanoid habitus (tall, slim, span>height, upper segment:lower
segment ratio <0.89, Arachodactyly)
Skin striae, hyperextensibility, thin skin or abnormal scarring
Eye signs: drooping eyelids or myopia or antimongoloid slant
Varicose veins or hernia or uterine/rectal prolapse
Mitral valve prolapse (by echocardiography)
HMS diagnosis requires
Two major criteria or
One major + two minor criteria or
Four minor criteria or
Two minor criteria and unequivocally aﬀected ﬁrst-degree relative
HMS is excluded by the presence of marfan or Ehlers-Danlos Syndromes.
Patients were excluded if they met any of the below
described criteria: (a) patients younger than 18 or older
than 50 years, in order to minimize the age related eﬀect
on joint laxity, (b) patients with a history of SpA which has
aﬀected joints that are calculated in the scoring method, (c)
patientswithanyotherpathologicalhypermobilitycondition
(e.g., acromegaly, hyperparathyroidism, chronic alcoholism,
rheumatic fever) [2].
The duration of oral steroid treatment was recorded for
both CD and UC patients for the period of the previous year
beforetheirentrytothestudy.Wealsoperformedasubgroup
analysis of the concomitant treatment in both CD and UC
patients in relation to joint hypermobility.
Another group of 96 employees of the hospital agreed
to participate and to serve as a control group. They were
screened and we excluded those with chronic diseases or
previouslytreatedwithsteroids.Theremainingcontrolswere
age and sex matched with patients.
All patients and control subjects gave their informed
consenttoparticipateinthestudy.Theresearchprotocolwas
approved by the Hospital’s Scientiﬁc Committee.
Statistical analyses were performed using the SPSS for
Windows package (version 11.0, SPSS, Chicago, IL). Data are
presented as medians along with minimum and maximum
values. The Chi square test and the Fisher’s exact test were
used when appropriate to compare the proportions of joint
hypermobility between the study groups. Odds ratios (OR)
and the 95% CI were calculated as well as the Relative Risk
(RR)ofJHinpatientswithCDandUC,comparedtohealthy
controls. The level of signiﬁcance was set at 0.05.Gastroenterology Research and Practice 3
Table 3: Demographic and clinical data of IBD patients and controls.
Crohn’s disease Ulcerative colitis Controls
N4 9 3 4 9 6
Number of participants 41 28 67
Sex (M/F) 22/19 15/13 38/29
Age (range)∗ 32 (18–50) 32.5 (18–49) 32 (18–50)
Disease duration in years (range)∗ 3 (0.1–21) 5 (0.1–20)
Patients on oral steroids the past year (%) 17 (41.4) 11 (39.2)
Joint Hypermobility (%) 29 (70.3) 10 (35.7) 17 (25.4)
Median Beighton Scores [range]
In total population 4 [0–9] 3 [0–8] 2.5 [0–9]
In hypermobile subjects 5 [4–9] 5 [4–8] 5 [4–9]
Articular Manifestations (%)
Spondylarthropathy (SpA)† 5 (12.2) 7 (25)
Hypermobility Syndrome (HMS) 5 (12.2) 1 (3.57)
Overlap symptoms (SpA & HMS) 7 (17.1) 0
Non speciﬁc or Degenerative Symptoms 11 (26.8) 7 (25)
Patients excluded from the study
Age restriction 5 5
Spondylarthropathies (AS) 3 1
∗Data are expressed as medians along with minimum and maximum values
†Arthritis which does not inﬂuence the Beighton score counting.
3. Results
A total of 150 Greek Caucasians (83 IBD patients and 67
healthy individuals) participated in the study. Sixty nine out
of 83 IBD patients (41 with CD and 28 with UC) were
ﬁnally eligible. Ten IBD patients were excluded due to age
restrictions. Three CD and one UC patients were excluded
due to ankylosing spondylitis (AS). Oral steroid treatment
for the past year was recorded in both groups in order to
detect any diﬀerences in cumulative steroid treatment which
may also interfere to the manifestation of joint laxity.
Overall 67 healthy controls were possible to be age and
sex matched with patients to avoid selection bias and they
ﬁnally included in the study. Demographical data of IBD
patients and controls are shown in Table 3.
Joint hypermobility was detected in 29 out of 41 CD
patients (70.7%), in 10 out of 28 UC patients (35.7%) and
in 17 out of 67 healthy control subjects (25.4%). There was
a signiﬁcant diﬀerence in the proportion of joint hypermo-
bility in CD patients as compared to UC patients (Fisher’s
exact two-tailed test: P = .0063) and healthy controls
(Fisher’s exact two-tailed test: P<. 0001). No diﬀerences
werefoundintheproportion ofjointhypermobilitybetween
UC patients and healthy controls (P = .3275).
The estimated odds ratios (OR) for joint hypermobility
were 7.108 (95% CI: 2.98–16.95) in CD patients and 1.634
(95% CI: 0.63–4.22) in UC patients, as compared to healthy
controls.
The relative risk for the coexistence of JH and CD is RR:
3.257 (95% CI 1.87–5.67), while the coexistence of JH and
UC is RR: 1.399 (95% CI: 0.74–2.63). According to these
data it is two times more likely that the underlying IBD in a
patient with joint hypermobility is CD rather than UC [RR:
1.859 (95% CI: 1.15–2.99)].
Analyzing data regarding their treatment we found that
seventeen patients with CD (41.4%) and eleven patients with
UC (39.3%) were on steroids during the previous year for
a median period of 3.17 months (range: 2–12) and 2.78
months [range: 2–12] respectively. The JH to Non-JH ratio
inCDpatientswhoweretreatedwithsteroidswas10:7while
in UC patients was 4:7. Interestingly, these data suggest that
there is no apparent eﬀect of steroid treatment in our cohort.
Concomitantimmunomodulatingandantibiotictherapy
in this cohort was also recorded (Table 4).
Although there are among CD patients treated with anti-
TNF alpha agents (Inﬂiximab or Adalimumab) an increased
numberofpatientsfulﬁllingourcriteriaforJHthediﬀerence
is not statistically signiﬁcant compared to those CD patients
who did not received the same treatment (Fisher’s exact
two-tailed test P = .452). Borderline insigniﬁcance on JH
was detected between CD and UC patients who received
aminosalycilateorazathioprine(Fisher’sexacttwo-tailedtest
P = .079 and P = .056 resp.).
In order to investigate the clinical relevance of JH we
analyzed the patterns of articular manifestations in our
cohort of IBD patients. A signiﬁcant proportion of articular
manifestations attributed to HMS were found among CD
patients. HMS was detected in 5 (12.2%) CD and in 1
(3.57%) UC patients [OR: 3.75 (95% CI: 0.41–34.007).
Additionally, there were 7 CD patients (17.1%), who had
overlapping symptoms for both HMS (Brighton’s major and
minor criteria 1 and 2), and early spondylarthropathy (i.e.,
artharalgias, enthesitis and longstanding inﬂammatory back
pain without radiographic evidence of permanent lesions)4 Gastroenterology Research and Practice
Table 4: Medication of IBD patients in relation to Joint Hypermo-
bility. A number of patients were on combination treatment (data
not shown).
Treatment Crohn’s disease N Ulcerative colitis N
(JH/Non-JH) (JH/Non-JH)
Steroids the last year 17 (10/7) 11 (3/8)
Aminosalycilates 19 (12/7) 20 (7/13)
Azathioprine 14 (11/3) 7 (2/5)
Anti-TNF 12 (10/2) 0
Antibiotics 5(3/2) 2 (1/1)
Methotrexate 1 (1/0) 1 (0/1)
Mercaptopourin 1 (0/1) 1 (0/1)
(Table 3). This overlap was not detected in patients with UC
who seem to have more overt symptoms and well deﬁned
articular manifestations such as degenerative spondylarthri-
tis and osteoarthritis or deﬁnite and radiographically evi-
denced SpA.
3.1. Discussion. In this study we demonstrate an increased
articular mobility in CD patients compared to UC patients
and healthy control subjects, while there were no diﬀerences
between UC patients and healthy controls. The estimated
Odds ratio for joint hypermobility in CD patients was 7.108
(95% CI: 2.98–16.95). To the best of our knowledge there is
no other study to correlate joint hypermobility with IBD.
The prevalence of JH is increased in childhood and
decreaseswithageinrelationwithotherfactorssuchasoccu-
pationalandmanualactivities,thusweusedanobservational
window consisted of ages between 18 and 50 years-old to
eliminate any age related eﬀect on joint mobility. We studied
a homogenous Caucasian Greek population, therefore due
to the ethnic diﬀerences in articular mobility [2–10], the
identiﬁcationinotherethnicgroupsofaconnectionbetween
IBD, especially CD and joint hypermobility could give an
indirectevidenceoftheimportanceofcollagenorconnective
tissue matrix involvement as part of the pathogenesis of the
intestinal disease.
There are no published data of JH in the Greek popula-
tion, although a large study in Greece has shown an overall
20% prevalence of low back pain, neck pain and soft tissue
rheumatism (i.e., tendinitis, bursitis, etc.) [11]. Patients and
controls in our cohort were enrolled from the grater region
of Thrace and central and eastern Macedonia, which are
accounted as the one forth of the Greek population so they
may considered representative. The prevalence of JH in our
controls is high (25.4%) and close to that reported in people
of Eastern rather than those of Western populations [6, 10].
In our cohort both CD and UC patients were treated
similarly in terms of oral steroids the year before their
recruitment. We found that the majority of UC patients
who were on steroid treatment had no features of JH, thus
there is no apparent eﬀect of steroids on articular mobility.
In a subgroup analysis of the concomitant medications a
signiﬁcant proportion of CD patients who were treated with
anti-TNF agents had Beighton scores suggesting JH but
there was not statistical diﬀerence among them and the CD
patients who were not on the speciﬁc treatment.
Joint hypermobility was not inﬂuenced by the type of
medication in both CD and UC patients. The apparent
predominance of JH on CD patients who were treated with
azathioprine or aminoalycilates is borderline insigniﬁcant
compared to JH in UC patients (P = .079 and P = .056,
resp.). A larger sample could possibly detect diﬀerences
which rather enhance the high prevalence of JH in CD than
the true eﬀect of these medications on joint laxity.
A rising question is whether JH is secondary to IBD. The
intestinal inﬂammation does not seem to be the primary
reason for secondary joint hypermobility in patients with
CD, since the median disease duration was higher in UC, 5
years [0.1–20] versus 3 years [0.1–21] in CD.
It is of particular interest that a large number of patients
with CD exhibit articular manifestations deﬁned as HMS.
This is reported for a ﬁrst time and provides to the clini-
cians important information regarding the interpretation of
musculoskeletal symptoms on patients with CD. Our study
accomplisharecentobservationthatpatientswithJHexhibit
unexplained gastrointestinal symptoms [12].
The incidence of SpAs including AS in our cohort is
within the range of 2%–20% reported in the literature for
CD patients (16.3%) and slightly higher in UC patients
(23.5%). [13] On the other hand, the hypermobility joint
syndrome has a 12.2% prevalence in CD versus 3.5% in
UC patients. Interestingly a substantial proportion (17.7%)
of patients with CD had overlapping joint symptoms,
which were arthralgia and/or inﬂammatory spinal pain
and this could indicate either premature SpA (i.e. without
radiographicevidenceofsacroiliitis)orHMS.Thus,articular
manifestations in a patient with CD should be interpreted
carefully in the direction of spondylarthropathy or HMS.
4. Conclusions
Joint hypermobility and the hypermobility syndrome are
common in Crohn’s disease patients in the Greek Caucasian
population while there is no diﬀerence on joint hypermobil-
ity in patients with ulcerative colitis compared to the healthy
control group. It is two times more likely that the underlying
IBD of a patient who exhibits joint hypermobility is CD
rather than UC. The constellation of articular symptoms
in CD patients does not always suggest an enteropathic
spondylarthropathy but the coexistent joint hypermobility.
The high incidence of this particular phenotype of JH on CD
patients could support the hypothesis that collagen varieties
may attribute to the pathogenesis of CD.
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